Exclusive Summary

• Best-in-Class potential as a highly sought-after obesity companion therapy: Engineered to combat GLP-1-induced muscle loss through a dual-mechanism targeting αActRII and αMyostatin.
• Delivers true "Functional Muscle Restoration" & "Bone Health": Unlike competitors that merely preserve mass, the 2nd generation UB352 significantly improves actual muscle grip strength and uniquely restores osteoblast differentiation for better bone density.
• Superior safety window with excellent patient compliance: Features ActRIIB-biased binding with muscle-focused myostatin inhibition to reduce off-target systemic effects, enabling low-dose (<100 mg), once-monthly subcutaneous self-injection.
• Remarkable dose-efficiency against clinical-stage competitors: Achieves comparable fat loss and lean mass preservation at only one-third (1/3) the dose of Bimagrumab.
• Exceptional Out-Licensing and co-development value: Already proven to be highly synergistic with Semaglutide in pre-clinical settings, making it a perfect "plug-and-play" asset for global Pharmas looking to dominate the next-generation, high-quality weight loss market.

Asset Materials

Contact Us for Full Materials